Here, we demonstrated that platinum-resistant cancer had a higher percentage of high BRCA2 level (87.5% vs 43.6%, <i>P</i> = 0.001), and that patients with a low BRCA2 level in cancer tissues had longer progression-free survival (with a median time of 28.0 vs 12.0 months, <i>P</i> < 0.001) and platinum-free duration (with a median time of 19.0 vs 5.0 months, <i>P</i> < 0.001) compared with those with a high BRCA2 level.